Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Identification of nitric oxide using lasers and sensors

Nitric oxide, a gas well known to scientists for its myriad functions, has proven challenging to measure accurately outside the laboratory. A team of Princeton and Rice University researchers has demonstrated a new method of identifying the gas using lasers and sensors that are inexpensive, compact and highly sensitive. Such a portable device, suitable for large-scale deployment, could be of great value to atmospheric science, pollution control, biology and medicine.

21 Sep 2009

Strategies for reducing tobacco use and health care costs in the U.S.

The Communities Putting Prevention to Work initiative announced today by the U.S. Department of Health and Human Services, which includes support for strategies to reduce tobacco use, is a smart investment in the nation's health that will save lives, prevent disease and help reduce health care costs.

18 Sep 2009

Genetically removing the osteopontin protein prevents lung diseases

In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).

16 Sep 2009

Novartis presents Phase II results of the QVA149 bronchodilator for the treatment of COPD

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announce that Novartis have presented the results of their two Phase II studies evaluating the efficacy, safety and tolerability of QVA149 at the annual congress of the European Respiratory Society (ERS) in Vienna.

16 Sep 2009

Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353

Biotie has started a clinical trial with its phosphodiesterase 4 (PDE4) inhibitor ELB353, having received the prerequisite regulatory and ethical clearances for the clinical trial application.

14 Sep 2009

Altair announces positive Phase I results for AIR645 in treating asthma

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.

14 Sep 2009

Chronic pediatric cough linked to reflux and allergies

New research shows that chronic cough in children is most often caused by gastroesophageal reflux and allergies. Researchers from Tulane University in New Orleans, LA, evaluated 40 patients aged 5 to 12 years with chronic cough (> 8 weeks in duration) with no obvious cause. Each patient underwent extensive multispecialty testing. Results showed that reflux was the single most commonly associated factor of chronic cough by itself (27.5 percent), followed by allergy (22.5 percent).

8 Sep 2009

COPD patients to have better protection against pneumonia with new vaccine

A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.

8 Sep 2009

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Dainippon Sumitomo Pharma Co., Ltd. (“DSP”, TSE: 4506) and Sepracor Inc. (“Sepracor”, Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.

3 Sep 2009

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Bio-Matrix Scientific Group, Inc. Chairman & CEO David Koos commented on the Company’s new opportunities in stem cell research, cancer treatment and intellectual property.

1 Sep 2009

Researchers develop an index scale to help physicians predict a patient's risk of dying from COPD

Researchers have developed an index scale to help physicians predict a patient's risk of dying from chronic obstructive pulmonary disease (COPD). The ADO index can help physicians assess the severity of a patient's illness to determine the appropriate level of treatment. COPD, which comprises emphysema and chronic bronchitis, is a major public health problem and it is the fourth leading cause of death in the U.S. The study of the ADO index is published in the August 29 edition of the Lancet.

29 Aug 2009

New risk index for COPD developed to estimate the risk of death

Researchers from the Centre for Research in Environmental Epidemiology (CREAL) and the Municipal Institute of Medical Research (IMIM-Hospital del Mar), in collaboration with the Hospital Clínic of Barcelona, have participated in an international consortium that has developed a new risk index for COPD patients. With this index, doctors can assess disease severity more objectively and estimate the risk of death.

28 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Research study reveals that mortality remains high in patients with pulmonary arterial hypertension

Mortality remains high among patients with pulmonary arterial hypertension awaiting lung transplant, despite changes to the allocation system that were designed to reduce mortality and increase the equitable distribution of donor organs, according to new research out of University of California San Francisco.

24 Aug 2009

Smoke free hospital campuses in USA by end of 2009

A new study from The Joint Commission projects that a majority of U.S. hospitals will have a smoke-free campus by the end of 2009. The study, "The Adoption of Smoke-Free Hospital Campuses in the United States," appears in the latest online issue of Tobacco Control, a British Medical Journal Group publication.

21 Aug 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

Joseph F. Finn, Jr., C.P.A. , announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.

19 Aug 2009

Results of Phase IIb dose range finding of oglemilast in chronic obstructive pulmonary disease announced

Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.

19 Aug 2009

Amira Pharmaceuticals submits IND for inflammatory and allergic disease treatment candidate

Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Food and Drug Administration.

19 Aug 2009

Tiotropium - corticosteroid combination improves lung disease survival

Sufferers of chronic obstructive pulmonary disease have a greater chance of survival when treated with a combination of drugs that includes tiotropium, according to research at the University of Illinois at Chicago.

12 Aug 2009

Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Identification of nitric oxide using lasers and sensors

Strategies for reducing tobacco use and health care costs in the U.S.

Genetically removing the osteopontin protein prevents lung diseases

Novartis presents Phase II results of the QVA149 bronchodilator for the treatment of COPD

Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353

Altair announces positive Phase I results for AIR645 in treating asthma

Chronic pediatric cough linked to reflux and allergies

COPD patients to have better protection against pneumonia with new vaccine

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Researchers develop an index scale to help physicians predict a patient's risk of dying from COPD

New risk index for COPD developed to estimate the risk of death

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Research study reveals that mortality remains high in patients with pulmonary arterial hypertension

Smoke free hospital campuses in USA by end of 2009

Aton Pharma markets preservative-free drugs for glaucoma

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

Results of Phase IIb dose range finding of oglemilast in chronic obstructive pulmonary disease announced

Amira Pharmaceuticals submits IND for inflammatory and allergic disease treatment candidate

Tiotropium - corticosteroid combination improves lung disease survival

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in